Merck & Co., Inc. $MRK Shares Acquired by Inman Jager Wealth Management LLC

Inman Jager Wealth Management LLC boosted its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 11.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 17,272 shares of the company’s stock after acquiring an additional 1,811 shares during the quarter. Inman Jager Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,367,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Legend Financial Advisors Inc. acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at $25,000. Barnes Dennig Private Wealth Management LLC acquired a new stake in Merck & Co., Inc. in the 1st quarter valued at $27,000. CBIZ Investment Advisory Services LLC lifted its holdings in Merck & Co., Inc. by 141.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after purchasing an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC purchased a new position in Merck & Co., Inc. in the 1st quarter valued at $36,000. Finally, Chung Wu Investment Group LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 1.7%

NYSE MRK opened at $86.02 on Friday. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $111.58. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The business’s fifty day simple moving average is $83.47 and its 200-day simple moving average is $81.47. The firm has a market cap of $214.87 billion, a PE ratio of 13.25, a P/E/G ratio of 0.88 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion for the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, October 7th. Investors of record on Monday, September 15th were given a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.92%.

Analysts Set New Price Targets

MRK has been the topic of a number of research reports. Morgan Stanley decreased their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday. Wells Fargo & Company decreased their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Finally, Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the company from $100.00 to $90.00 in a report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $104.31.

Get Our Latest Stock Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.